Osman İlhami Özcebe

Er schloss 1984 die Medizinische Fakultät der Universität Hacettepe als Jahrgangsbester ab. Seine Facharztausbildung in Innerer Medizin beendete er 1990 in Hacettepe. Dr. Özcebe, verheiratet und Vater zweier Kinder, schloss 1993 in derselben Abteilung die Subspezialisierung in Hämatologie ab, wurde 1995 Dozent (Assoz. Prof.) und 2002 Professor.

1997 absolvierte er ein Jahr lang an der University of Pennsylvania in den Vereinigten Staaten eine Ausbildung in Blutbankwesen, Transfusionsmedizin und Apheresepraxis. Derzeit arbeitet er als Hochschullehrer in der Wissenschaftlichen Einheit für Hämatologie der Abteilung für Innere Medizin und ist seit 1998 Direktor des Blutzentrums und der Apherese-Einheit der Universitätskliniken Hacettepe. Während seiner Zeit als Direktor des Blutzentrums verwirklichte er das Projekt zur Modernisierung des Blutzentrums und der Apherese-Einheit. Gleichzeitig wirkte er in verschiedenen Kommissionen des Gesundheitsministeriums mit und trug dazu bei, die gesetzlichen Vorschriften zu Blutbankwesen und Apherese an die Rechtsvorschriften der Europäischen Union anzupassen.

Er ist Gründungsmitglied der Türkischen Apheresegesellschaft und war 4 Jahre lang deren Generalsekretär und 1 Jahr lang Präsident. Er war Vorsitzender des Unterkomitees für Transfusionsmedizin der Türkischen Hämatologischen Gesellschaft sowie im Gesundheitsministerium Mitglied der Wissenschaftlichen Kommission der Blutzentren, des Beirats für Blut und Blutprodukte, der Ausbildungskommission für Blutdienste, der Kommission für Apherese/Photopherese und der Wissenschaftlichen Kommission für therapeutische Apherese.

Bis 2013 war er 7 Jahre lang Leiter der Hämatologie-Einheit der Abteilung für Innere Medizin der Medizinischen Fakultät der Universität Hacettepe.

1. Effect of therapeutic plasma exchange on antimicrobials in critically ill patientsBalaban U., Kara E., Kaya E. K., Özcebe O. İ., Akova M., Topeli İskit A., et al.CRITICAL CARE, cilt.28, sa.1, 2024 (SCI-Expanded, Scopus)
2. Examination of drug removal profiles in patients undergoing therapeutic plasma exchange: A retrospective studyBalaban U., Kara E., Mahmoud S. H., Özcebe O. İ., Demirkan S. K.THERAPEUTIC APHERESIS AND DIALYSIS, cilt.28, sa.6, ss.954-963, 2024 (SCI-Expanded, Scopus)
3. Antimicrobial management in patients undergoing therapeutic plasma exchange: A Cross-Sectional Nationwide SurveyBalaban U., Kara E., Pınar A., Özcebe O. İ., Demirkan S. K., Ünal S.JOURNAL OF INVESTIGATIVE MEDICINE, cilt.72, sa.8, ss.920-929, 2024 (SCI-Expanded, Scopus)
4. Hypophosphatemia related to the use of ibrutinibKARADENİZ M., ÇINAR O. E., Erdogdu B., MALKAN Ü. Y., GÖKER H., ÖZCEBE O. İ.Journal of Oncology Pharmacy Practice, 2023 (SCI-Expanded, Scopus)
5. A single-center experience of haploidentical stem cell transplantation in hematological malignanciesMALKAN Ü. Y., GÖKER H., DEMİROĞLU H., Tekin F., Akdemir B., ALADAĞ KARAKULAK E., et al.Turkish Journal of Medical Sciences, cilt.53, sa.1, ss.352-359, 2023 (SCI-Expanded, Scopus, TRDizin)
6. Hemoglobin cast nephropathy: a rare but serious complication of hemolysis in a pediatric patientBALTU D., Oral N. A., KESİCİ S., TOPALOĞLU R., ÖZCEBE O. İ., AKSU T., et al.Turkish Journal of Pediatrics, cilt.65, sa.5, ss.874-880, 2023 (SCI-Expanded, Scopus, TRDizin)
7. Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantationKARATAŞ A., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., Velet M., ÇINAR O. E., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.2, ss.413-419, 2022 (SCI-Expanded, Scopus, TRDizin)
8. Platelet-rich plasma treatment improves postoperative recovery in patients with pilonidal sinus disease: a randomized controlled clinical trialBoztug C. Y., KARAAĞAÇ AKYOL T., Benlice C., KOÇ M. A., Doganay Erdogan B., ÖZCEBE O. İ., et al.BMC SURGERY, cilt.21, sa.1, 2021 (SCI-Expanded, Scopus)
9. Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemiaALADAĞ KARAKULAK E., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.60, sa.2, 2021 (SCI-Expanded, Scopus)
10. Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic LeukemiaALADAĞ KARAKULAK E., Aktimur S. H., Aydin O., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., et al.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.3, ss.147-153, 2021 (SCI-Expanded, Scopus)
11. Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry)KUMAN TUNÇEL Ö., Kayikcioglu M., PIRILDAR Ş., YILMAZ M., KAYNAR L., Aktan M., et al.JOURNAL OF CLINICAL LIPIDOLOGY, cilt.14, sa.3, ss.361-372, 2020 (SCI-Expanded, Scopus)
12. Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry)Kayikcioglu M., Kuman-Tuncel O., Pirildar S., YILMAZ M., KAYNAR L., Aktan M., et al.JOURNAL OF CLINICAL LIPIDOLOGY, cilt.13, sa.3, ss.455-467, 2019 (SCI-Expanded, Scopus)
13. The Turkish experience with therapeutic plasma exchange: A national surveyKorkmaz S., Medeni S. S., DEMİRKAN F., Besisik S. K., Dadin S. A., ÇAĞLIYAN G. A., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.58, sa.3, ss.287-292, 2019 (SCI-Expanded, Scopus)
14. CYTOGENETIC ANOMALIES IN MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER STUDYBOZKURT S., BÜYÜKAŞIK Y., DEMİROĞLU H., ALADAĞ KARAKULAK E., OKAY M., KARATAŞ A., et al.Genetics and Application, cilt.3, sa.1, ss.51-56, 2019 (Hakemli Dergi)
15. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiencyALADAĞ KARAKULAK E., AKSU S., DEMİROĞLU H., SAYINALP N., GÖKER H., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.5, ss.1560-1563, 2019 (SCI-Expanded, Scopus, TRDizin)
16. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphomaOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., et al.TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.4, ss.985-992, 2019 (SCI-Expanded, Scopus, TRDizin)
17. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?Kayikcioglu M., Tokgozoglu L., DOĞAN V., CEYHAN C., TUNÇEZ A., KUTLU M., et al.ATHEROSCLEROSIS, cilt.277, ss.341-346, 2018 (SCI-Expanded, Scopus)
18. Evaluation of Secondary Malignancies in Chronic Lymphocytic LeukemiaDEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.Journal of Global Oncology, ss.205, 2018 (ESCI)
19. Therapeutic plasma exchange for refractory SLE:A comparison of outcomes between different sub-phenotypesSoyuoz A., KARADAĞ Ö., Karaagac T., KILIÇ L., Bilgen Ş. Ş., ÖZCEBE O. İ.EUROPEAN JOURNAL OF RHEUMATOLOGY, cilt.5, sa.1, ss.32-36, 2018 (ESCI, TRDizin)
20. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)Kayikcioglu M., Tokgozoglu L., YILMAZ M., KAYNAR L., Aktan M., Durmus R. B., et al.ATHEROSCLEROSIS, cilt.270, ss.42-48, 2018 (SCI-Expanded, Scopus)
21. A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 studyTekgunduz E., YILMAZ M., ERKURT M. A., KİKİ İ., Kaya A. H., KAYNAR L., et al.TRANSFUSION AND APHERESIS SCIENCE, cilt.57, sa.1, ss.27-30, 2018 (SCI-Expanded, Scopus)
22. Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic LeukemiaKARCIOĞLU A. M., OKAY M., BÜYÜKAŞIK Y., Malkan Ü. Y., SAYINALP N., DEMİROĞLU H., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.28, sa.4, ss.254-260, 2018 (SCI-Expanded, Scopus, TRDizin)
23. The impact of chemo/immune therapy-related cytopenias on the clinical course of chronic lymphoid leukemiaMalkan Ü. Y., OKAY M., HAZNEDAROĞLU İ. C., GÜNEŞ G., Aslan N. A., ÖZCEBE O. İ., et al.LEUKEMIA & LYMPHOMA, cilt.58, ss.96, 2017 (SCI-Expanded)
24. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosisMalkan Ü. Y., ÖZCEBE O. İ.TRANSFUSION AND APHERESIS SCIENCE, cilt.56, sa.6, ss.880-882, 2017 (SCI-Expanded, Scopus)
25. Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in RemissionAYDIN M. S., BOZKURT S., GÜNEŞ G., Malkan Ü. Y., Aslan T., ETGÜL S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.34, sa.1, ss.103-104, 2017 (SCI-Expanded, Scopus, TRDizin)
26. Comparison of Myelodysplastic Syndrome Prognostic Scoring SystemsBEKTAŞ Ö., ÜNER A., ELİAÇIK E., Uz B., Isik A., ETGÜL S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.33, sa.2, ss.119-126, 2016 (SCI-Expanded, Scopus, TRDizin)
27. The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical PracticeMalkan Ü. Y., GÜNEŞ G., GÖKER H., HAZNEDAROĞLU İ. C., Acar K., ELİAÇIK E., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.33, sa.4, ss.281-285, 2016 (SCI-Expanded, Scopus, TRDizin)
28. The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute LeukemiasMalkan U. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., Yayar O., ETGÜL S., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.26, sa.1, ss.54-60, 2016 (SCI-Expanded, Scopus, TRDizin)
29. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative DiseasesAktimur S. H., Malkan U. Y., Eyupoglu D. N., HAZNEDAROĞLU İ. C., KELKİTLİ E., Atay H. M., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.26, sa.3, ss.153-158, 2016 (SCI-Expanded, Scopus, TRDizin)
30. High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiologyBEKTAŞ Ö., ÜNER A., Aydin S. M., ELİAÇIK E., Uz B., Isik A., et al.INTERNATIONAL JOURNAL OF HEMATOLOGY, cilt.102, sa.2, ss.211-217, 2015 (SCI-Expanded, Scopus)
31. The factors affecting early death after the initial therapy of acute myeloid leukemiaMalkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., ETGÜL S., Aslan T., et al.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.8, sa.12, ss.22564-22569, 2015 (SCI-Expanded, Scopus)
32. Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete RemissionMalkan Ü. Y., Gunes G., Isik A., Eliacik E., Etgul S., Aslan T., et al.ACTA HAEMATOLOGICA, cilt.134, sa.1, ss.32-37, 2015 (SCI-Expanded, Scopus)
33. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative NeoplasmsELİAÇIK E., Isik A., AKSU S., ÜNER A., BÜYÜKAŞIK Y., SAYINALP N., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.32, sa.2, ss.163-167, 2015 (SCI-Expanded, Scopus, TRDizin)
34. Clinicopathological associations of acquired erythroblastopeniaGÜNEŞ G., Malkan Ü. Y., YAŞAR H. A., ELİAÇIK E., HAZNEDAROĞLU İ. C., DEMİROĞLU H., et al.INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.8, sa.12, ss.22515-22519, 2015 (SCI-Expanded, Scopus)
35. Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical ManagementGÜNEŞ G., Malkan Ü. Y., AKSU S., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., et al.BLOOD, cilt.124, sa.21, 2014 (SCI-Expanded, Scopus)
36. Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete RemissionMalkan Ü. Y., GÜNEŞ G., GÖKER H., ELİAÇIK E., Isik A., SAYINALP N., et al.BLOOD, cilt.124, sa.21, 2014 (SCI-Expanded, Scopus)
37. Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor CellsUz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz O., AKSU S., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.31, sa.2, ss.136-142, 2014 (SCI-Expanded, Scopus, TRDizin)
38. Vitamin B-12 Deficiency with the Absence of Anemia in Young and Middle-Aged PopulationKara A., Eliacik E., BÜYÜKAŞIK Y., ÖZCEBE O. İ., Haznedaroglu I., AKSU S., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.24, sa.3, ss.190-194, 2014 (SCI-Expanded, Scopus, TRDizin)
39. An Immune Thrombocytopenic Purpura-Like Picture Preceding Chronic Myelomonocytic Leukemia: A Case Series and Review of the LiteratureAlbayrak M., ELİAÇIK E., KORUCU B., Isik A., GÜNEŞ G., AKSU S., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.24, sa.3, ss.213-216, 2014 (SCI-Expanded, Scopus, TRDizin)
40. Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disordersUz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Ng O. H., BÜYÜKAŞIK Y., et al.JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, cilt.14, sa.4, ss.308-314, 2013 (SCI-Expanded, Scopus)
41. Co-expression of t(5;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the LiteratureUz B., ELİAÇIK E., Isik A., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.30, sa.4, ss.400-404, 2013 (SCI-Expanded, Scopus, TRDizin)
42. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylateUz B., BÜYÜKAŞIK Y., Atay H., KELKİTLİ E., Turgut M., BEKTAŞ Ö., et al.HEMATOLOGY, cilt.18, sa.5, ss.247-252, 2013 (SCI-Expanded, Scopus)
43. Spot analyses of serum neopterin, tryptophan and kynurenine levels in a random group of blood donor populationUnuvar S., GİRGİN G., PALABIYIK Ş. S., Karaagac T., ÖZCEBE O. İ., Sahin G., et al.PTERIDINES, cilt.24, sa.1, ss.41-46, 2013 (SCI-Expanded, Scopus)
44. Review of therapeutic options and the management of patients with myelodysplastic syndromesÖZCAN M. A., İLHAN O., ÖZCEBE O. İ., Nalcaci M., Gulbas Z.EXPERT REVIEW OF HEMATOLOGY, cilt.6, sa.2, ss.165-189, 2013 (SCI-Expanded, Scopus)
45. Renin-Angiotensin System (RAS) Expressions in Myeloid Leukemic Cell LinesUz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz Ng O., BÜYÜKAŞIK Y., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.23, sa.4, ss.264-268, 2013 (SCI-Expanded, Scopus, TRDizin)
46. Bone Marrow Iron Staining is a Reliable Test for Elimination of Iron Deficiency Anemia Rather than its DiagnosisKoca E., Cetiner D. A., BÜYÜKAŞIK Y., ÜNER A., SAYINALP N., HAZNEDAROĞLU İ. C., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.23, sa.4, ss.260-263, 2013 (SCI-Expanded, Scopus, TRDizin)
47. Nasal Natural Killer/T-cell Lymphoma with Skin, Eye, and Peroneal Nerve InvolvementTurker B., Uz B., Isik M., BEKTAŞ Ö., DEMİROĞLU H., SAYINALP N., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.29, sa.4, ss.413-419, 2012 (SCI-Expanded, Scopus, TRDizin)
48. An Evaluation of Hormone Levels in Behcet's DiseaseKarakus S., Nar A., Toprak S. K., Atalay F., ÖZCEBE O. İ.TURKISH JOURNAL OF RHEUMATOLOGY, cilt.27, sa.3, ss.158-164, 2012 (SCI-Expanded, Scopus, TRDizin)
49. How do we collect better granulocyte?Akyol T. K., Buyukasik Y., Aksu S., Ozcebe O. I.TRANSFUSION AND APHERESIS SCIENCE, cilt.47, sa.1, ss.107-111, 2012 (SCI-Expanded, Scopus)
50. Discovering Blood Donor Arrival Patterns Using Data Mining: A Method to Investigate Service Quality at Blood CentersTESTİK M. C., OZKAYA B., AKSU S., ÖZCEBE O. İ.JOURNAL OF MEDICAL SYSTEMS, cilt.36, sa.2, ss.579-594, 2012 (SCI-Expanded, SSCI, Scopus)
51. Toscana Virus (TOSV) exposure is confirmed in blood donors from Central, North and South/Southeast Anatolia, TurkeyERGÜNAY K., AYDOĞAN S. H., ÖZCEBE O. İ., Cilek E. E., Hacioglu S., Karakaya J., et al.ZOONOSES AND PUBLIC HEALTH, cilt.59, sa.2, ss.148-154, 2012 (SCI-Expanded, Scopus)
52. Hunter syndrome and new onset idiopathic thrombocytopenic purpura in a young patientUz B., DEMİROĞLU H., ÖZCEBE O. İ.ANNALS OF HEMATOLOGY, cilt.91, sa.2, ss.303-304, 2012 (SCI-Expanded, Scopus)
53. Unusual Extramedullary Recurrence and Renal Relapse Despite Complete Chimerysm after Allografting in Ph+ ALLSerefhanoglu S., GÖKER H., BAYDAR D., ÜNER A., ARICI M., HAZNEDAROĞLU İ. C., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, sa.1, ss.46-50, 2012 (SCI-Expanded, Scopus, TRDizin)
54. Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuriaGÖKER H., Uz B., BÜYÜKAŞIK Y., AKSU S., Haznedaroglu I., SAYINALP N., et al.TURKISH JOURNAL OF HEMATOLOGY, cilt.28, sa.3, ss.223-227, 2011 (SCI-Expanded, Scopus, TRDizin)
55. Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemiaSerefhanoglu S., BÜYÜKAŞIK Y., Emmungil H., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., et al.INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, cilt.8, sa.1, ss.30-38, 2011 (SCI-Expanded, Scopus)
56. THE FACTORS INFLUENCING OVERALL SURVIVAL IN NEWLY DIAGNOSED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTSSerefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetgner D., et al.JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, cilt.74, sa.1, ss.7-12, 2011 (ESCI, TRDizin)
57. Investigation of West Nile Virus Seroprevalence in Hacettepe University Hospital Blood Donors and Confirmation of the Positive Results by Plaque Reduction Neutralization TestAyturan S., AYDOĞAN S., ERGÜNAY K., ÖZCEBE O. İ., Us D.MIKROBIYOLOJI BULTENI, cilt.45, sa.1, ss.113-124, 2011 (SCI-Expanded, Scopus, TRDizin)
58. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapySEREFHANOGLU S., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., et al.LEUKEMIA RESEARCH, cilt.34, sa.12, 2010 (SCI-Expanded, Scopus)
59. Prognostic Factors Affecting the Clinical Course of non-Hodgkin's LymphomasBeyazit Y., Kekilli M., Purnak T., GÖKER H., AKSU S., HAZNEDAROĞLU İ. C., et al.UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.20, sa.2, ss.96-102, 2010 (SCI-Expanded, Scopus, TRDizin)
60. Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literatureSerefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., et al.MEDICAL ONCOLOGY, cilt.27, sa.1, ss.55-58, 2010 (SCI-Expanded, Scopus)

All 74 on AVESİS →

1. THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN’S LYMPHOMA: THE SINGLE CENTER EXPERIENCESAYINALP N., ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., AKSU S., DEMİROĞLU H., et al.15th International Conference on Malignant Lymphoma, İsviçre, 18 - 22 Haziran 2019, cilt.37, ss.366, (Özet Bildiri)
2. ASEMPTOMATİK D-DİMER YÜKSEKLİĞİ İMMÜNMONULATUAR KULLANAN MULTİPLE MYELOMADA TROMBOZU TAHMİN EDER Mİ: GERÇEK YAŞAM VERİSİAYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., YAZGAN S. Ç., DEMİROĞLU H., ÖZCEBE O. İ., et al.4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)
3. ALLOJENİK KÖK HÜCRE NAKLİ SONRASI RELAPS İZLENEN AKUT LÖSEMİ HASTALARINDA TEDAVİ SEÇENEKLERİ: DONÖR LENFOSİT İNFUZYONU VE İKİNCİ ALLOJENİK KÖK HÜCRE NAKLİNİN KARŞILAŞTIRILMASIALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., ÇİFTÇİLER R., SAYINALP N., et al.4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Nisan 2019, (Özet Bildiri)
4. MULTİPLE MYELOM HASTALARINDA İNDUKSİYON TEDAVİ SÜRESİNİN SAĞKALIMA ETKİSİALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., et al.3. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Türkiye, 8 - 09 Mart 2019, (Özet Bildiri)
5. T HÜCRELİ LENFOMA HASTALARININ KLİNİK ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ: TANIDAN PROGNOZA TEK MERKEZ DENEYİMİDEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)
6. MRG’DE TESADÜFEN SAPTANAN KEMİK İLİĞİNİN DİFFÜZ SİNYAL DEĞİŞİKLİKLERİ LENFOHEMATOPOETİK HASTALIKLARI ÖNGÖREBİLİR Mİ?ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., et al.44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.266, (Özet Bildiri)
7. LENALIDOMID İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİBE KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIMDEMİROĞLU H., AKSU S., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., et al.TÜRK HEMATOLOJİ DERNEĞİ, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)
8. AĞIR APLASTİK ANEMİ HASTALARINDA HEMATOPOETİK KÖK HÜCRE NAKLİNDE KULLANILAN HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASIALADAĞ KARAKULAK E., DEMİROĞLU H., ÇİFTÇİLER R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., et al.44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.261, (Özet Bildiri)
9. BRENTIXUMAB VEDOTIN IN CD30 LYMPHOMAS: SINGLE CENTER EXPERIENCEDEMİROĞLU H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÖKER H., et al.IX. INTERNATIONAL EHOC, 17 - 20 Ekim 2018, cilt.73, (Tam Metin Bildiri)
10. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphomaOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., CIFTCILER R., Aladag E., et al.9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Türkiye, 17 - 20 Ekim 2018, cilt.73, (Özet Bildiri)
11. RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANNTRON-MELFALAN HAZIRLAMA REJİMİOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., malkan Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., et al.6. HEMATOLOJİK ONKOLOJİ KONGRESİ, Türkiye, 18 - 22 Eylül 2018, (Tam Metin Bildiri)
12. RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANTRON-MELFALAN HAZIRLAMA REJİMİOKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., et al.5. HEMATOLOJİK ONKOLOJİ KONGRESİ, Kıbrıs (Kktc), 20 - 22 Eylül 2018, (Özet Bildiri)
13. AKUT MYELOİD LÖSEMİLİ BİR OLGULDA SİTOZİN ARABİNOZİD İLİŞKİLİ PULMONER TOKSİSİTEÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., AKSU S., DEMİROĞLU H., GÖKER H., et al.4.İLAÇ VE TEDAVİ KONGRESİ, Kıbrıs (Kktc), 19 - 23 Eylül 2018, ss.254, (Özet Bildiri)
14. EFFECT OF THE INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTSALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., et al.The International Congress of BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, (Özet Bildiri)
15. DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATAAYDIN M. S., YAZGAN S. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., KELKİTLİ E., TURGUT M., et al.23rd Congress of EHA, Stockholm, İsveç, 14 - 17 Haziran 2018, (Özet Bildiri)
16. Does Asymptomatic D-Dimer Elevation Predict Thrombosis in Patient on Immunomodulatory Drugs in Multiple Myeloma: Real-Life DataAYDIN M. S., YAZGAN S. C., ALADAĞ KARAKULAK E., Çiftçiler R., KELKİTLİ E., TURGUT M., et al.European Hemtology Association, 14 - 17 Haziran 2018, (Özet Bildiri)
17. KRONİK LENFOSİTİK LÖSEMİ HASTALARINDA İKİNCİL MALİGNİTELERİN DEĞERLENDİRİLMESİALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., HEZİYEV T., BÜYÜKAŞIK Y., SAYINALP N., et al.2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Kıbrıs (Kktc), 4 - 06 Mayıs 2018, (Özet Bildiri)
18. Common medical problems in adult patients with Hemophilia A: A single center experienceAYDIN M. S., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H., et al.15. INTERNATIONAL HEMOPHILIA CONGRESS OF TURKEY, İstanbul, Türkiye, 4 - 07 Nisan 2018, (Özet Bildiri)
19. EFFECT OF INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTSDEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., et al.INTERNATIONAL CONGRESS OF BMT 2018, Busan, Güney Kore, 30 Ağustos - 01 Eylül 2018, cilt.53, (Tam Metin Bildiri)
20. A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 StudyTekgunduz E., YILMAZ M., ERKURT M. A., KİKİ İ., KAYA E., KAYNAR L., et al.58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)
21. AN ACUTE MYELOID LEUKEMIA PATIENT COMPLICATED WITH HYPERLEUKOCYTOSISMalkan Ü. Y., GÜNEŞ G., Yayar O., HAZNEDAROĞLU İ. C., AKSU S., ÖZCEBE O. İ.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
22. SUCCESSFUL TREATMENT OF RESISTANT CHRONIC GRAFT VERSUS HOST DISEASE WITH EXTRACORPOREAL PHOTOPHERESIS IN A PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENT WHO HAS UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATIONMalkan Ü. Y., GÜNEŞ G., ELİAÇIK E., Yayar O., GÖKER H., ÖZCEBE O. İ.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
23. A CHRONIC MYELOID LEUKEMIA CASE WHO HAS DISCONTINUED IMATINIB TREATMENTMalkan Ü. Y., GÜNEŞ G., Aslan T., Yayar O., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C.6th International Eurasian Hematology Congress, Antalya, Türkiye, 14 - 18 Ekim 2015, cilt.39, (Özet Bildiri)
24. Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard AdministrationGÖKER H., ELİAÇIK E., Altuntas F., Tekgunduz E., ÖZDEMİR E., Isik A., et al.56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri)
25. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CMLAKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., et al.20th Congress of the European Hematology Association Vienna, Austria June 11-14, 2015, 11 - 14 Haziran 2014, (Tam Metin Bildiri)
26. DASATİNİB KULLANIRKEN PLEVRAL EFFÜZYONU GELİŞİP, KÜÇÜK HÜCRELİ AKCİĞER KANSERİ TANISI ALAN BİR OLGUÇİFTÇİLER R., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., AKSU S., et al.
27. Erken Evre Kronik Lenfositer Löseminin Nadir Görünümleri ve Bir Mide Kanseri Vakası Birlikteliği: 2 vaka sunumu.AYDIN M. S., ÜNER A., OKAY M., MALKAN Ü. Y., BÜYÜKAŞIK Y., ÖZCEBE O. İ., et al.
28. RARE PRESENTATIONS OF EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA AND A COINCIDENCE WITH GASTRIC CANCER: 2 CASESAYDIN M. S., ÜNER A., malkan Ü. Y., OKAY M., BÜYÜKAŞIK Y., ÖZCEBE O. İ., et al.
29. The Impact of Chemo/Immune Therapy-­‐Related Cytopeniason the Clinical Course of Chronic Lymphoid LeukemiaOKAY M., HAZNEDAROĞLU İ. C., malkan Ü. Y., GÜNEŞ G., aslan n., AKSU S., et al.